Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase

Circulation

Volumn 106, Issue 7, 2002, Pages 873-879

  Feng, Qingping ^a   Song, Wei ^a   Lu, Xiangru ^a   Hamilton, Joel A ^a   Lei, Ming ^a   Peng, Tianqing ^a   Yee, Siu Pok ^a,b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Apoptosis; Heart defects, congenital; Heart failure; Heart septal defects; Nitric oxide

Indexed keywords

CASPASE 3; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPSY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EMBRYO; ENZYME ACTIVITY; HEART ATRIUM SEPTUM DEFECT; HEART DEVELOPMENT; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE SEPTUM DEFECT; HISTOPATHOLOGY; LUNG CONGESTION; MORTALITY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; ULTRASOUND; WILD TYPE;

ANIMALS; APOPTOSIS; CASPASES; DISEASE MODELS, ANIMAL; HEART; HEART ATRIA; HEART FAILURE, CONGESTIVE; HEART SEPTAL DEFECTS; HEART VENTRICLES; HETEROZYGOTE; HOMOZYGOTE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; SURVIVAL RATE;

EID: 0037072469     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000024114.82981.EA     Document Type: Article

References (29)

1. Feng Q, Hedner T. Endothelium-derived relaxing factor (EDRF) and nitric oxide (NO), I: physiology, pharmacology and pathophysiological implications. Clin Physiol. 1990;10:407-426.
2. Forstermann U, Close EI, Pollock JS, et al. Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension. 1994;23:1121-1131.
3. Bloch W, Fleischmann BK, Lorke DE, et al. Nitric oxide synthase expression and role during cardiomyogenesis. Cardiovasc Res. 1999;43:675-684.
4. Balligand JL, Kelly RA, Marsden PA, et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A. 1993;90:347-351.
5. Kanai AJ, Mesaros S, Finkel MS, et al. β-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol. 1997;273:C137-C1377.
6. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res. 1996;79:363-380.
7. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res. 1999;43:595-606.
8. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567-2578.
9. Dimmeler S, Haendeler J, Nehls M, et al. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-1ike like proteases. J Exp Med. 1997;185:601-607.
10. Kim Y-M, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem. 1997:272:31138-31148.
11. Pexieder T. Cell death in the morphogenesis and teratogenesis of the heart. Adv Anat Cell Biol. 1975;51:1-99.
12. Watanabe M, Choudhry A, Berlan M, et al. Developmental remodeling and shortening of the cardiac outflow tract involves myocyte programmed cell death. Development. 1998;125:3809-3820.
13. Abdelwahid E, Pelliniemi LJ, Niinikoski H, et al. Apoptosis in the pattern formation of the ventricular wall during mouse heart organogenesis. Anat Rec. 1999;256:208-217.
14. Zhao Z, Rivkees SA. Programmed cell death in the developing heart: regulation by BMP4 and FGF2. Dev Dyn. 2000;217:388-400.
15. Kajstura J, Mansukhani M, Cheng W, et al. Programmed cell death and expression of the protooncogene bcl-2 in myocytes during postnatal maturation of the heart. Exp Cell Res. 1995;219:110-121.
16. Webb S, Brown NA, Anderson RH. Formation of the atrioventricular septal structures in the normal mouse. Circ Res. 1998;82:645-656.
17. Lee TC, Zhao YD, Courtman DW, et al. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation. 2000;101:2345-2348.
18. Pexieder T. Standardized method for study of normal and abnormal cardiac development in chick, rat, mouse, dog and human embryos. Teratology. 1986;33:91C-92C.
19. Gruber PJ, Kubalak SW, Pexieder T, et al. RXR α deficiency confers genetic susceptibility for aortic sac, conotruncal atrioventricular cushion, and ventricular muscle defects in mice. J Clin Invest. 1996;98:1332-1343.
20. Feng Q, Lu X, Jones DL, et al. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality post-myocardial infarction in mice. Circulation. 2001;104:700-704.
21. Song W, Lu X, Feng Q. Tumor necrosis factor-α induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc Res. 2000;45:595-602.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
23. Payne RM, Johnson MC, Grant JW, et al. Toward a molecular understanding of congenital heart disease. Circulation. 1995;91:494-504.
24. Edwards WD. Congenital heart disease. In: Damjanov I, Linder J, eds. Anderson's Pathology. 10th ed. St Louis, Mo: Mosby-Year Book Inc; 1996:1339-1396.
25. Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43-50.
26. Schwartz SM. Cell death and the caspase cascade. Circulation. 1998;97:227-229.
27. Gregg AR, Schauer A, Shi O, et al. Limb reduction defects in endothelial nitric oxide synthase-deficient mice. Am J Physiol. 1998;275:H2319-H2324.
28. Basson CT, Cowley GS, Solomon SD, et al. The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome). N Engl J Med. 1994;330:885-891.
29. Gelb BD, Zhang J, Sommer RJ, et al. Familial patent ductus arteriosus and bicuspid aortic valve with hand anomalies: a novel heart-hand syndrome. Am J Med Genet. 1999;87:175-179.